Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 38 member 10 (SLC38A10)
- Target
- SLC38A10
- Molecular classification
- Transporter, Sodium-coupled neutral amino acid transporter, Solute carrier protein
01
Overview
Solute carrier family 38 member 10 is a sodium-coupled neutral amino acid transporter localized to the Golgi apparatus and endoplasmic reticulum. It facilitates the bidirectional transport of key amino acids such as glutamine, glutamate, and aspartate, and may act as a sensor within the glutamate-glutamine cycle, influencing neuronal signaling and cellular metabolism. Its dysregulation has been linked to cancer progression and neurological function, making it a candidate for disease association and potential therapeutic intervention. Recent studies indicate possible roles in cell survival (possibly in connection with p53), cancer prognosis, and metabolic adaptation, although clinical targeting is still under investigation
- Other names
- Putative sodium-coupled neutral amino acid transporter 10
02
Mechanism of action
For SLC38A10 targeting, proposed mechanisms would include inhibition of bidirectional amino acid transport, altering cellular metabolism, mTOR pathway modulation, and possibly apoptosis induction
03
Biological functions
Bidirectional transport of amino acids (such as glutamine, glutamate, and aspartate)Regulation of the glutamate-glutamine cycle and potentially acting as a glutamate sensorModulation of mTOR (mechanistic target of rapamycin) signaling in the brainPossible involvement in cell survival pathways (interaction with p53)
04
Disease associations
Cancer (especially in tumorigenesis and prognosis in cervical and other cancers, though specific clinical relevance of SLC38A10 is not yet fully established)Neurodegenerative disease (suggested due to neurotransmission roles)Other metabolic disorders (by analogy to other SLC family members)
05
Safety considerations
As with other SLC transporters, potential concerns in developing SLC38A10-targeted therapeutics include off-target effects on amino acid metabolism, neurotransmission, and metabolic homeostasis
06
Interacting drugs
No direct drugs reported for SLC38A10 specifically; however, drugs that target SLC family transporters (e.g., certain anti-cancer agents) may interact with similar proteins
07
Biomarkers
Downregulation in certain cancers (HPV-positive cervical neoplastic keratinocytes) may be prognosticSLC family members can be considered biomarkers for certain cancer progression and drug sensitivity
Beyond the preview
Go deeper on Solute carrier family 38 member 10 (SLC38A10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 38 member 10 (SLC38A10).